---
title: "Syros Pharmaceuticals, Inc. (SYRS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SYRS.US.md"
symbol: "SYRS.US"
name: "Syros Pharmaceuticals, Inc."
industry: "Biotechnology"
---

# Syros Pharmaceuticals, Inc. (SYRS.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.syros.com](https://www.syros.com) |

## Company Profile

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subse...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:13.000Z

**Overall: E (0.91)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 396 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -95.61% |  |
| Net Profit YoY | 6.81% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9391.36 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 386000.00 |  |


**Multi Score**: E

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -776.96% | E |
| Profit Margin | -25340.67% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -95.61% | E |
| Net Profit YoY | 6.81% | C |
| Total Assets YoY | -42.49% | E |
| Net Assets YoY | -130.64% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.39% | D |
| OCF YoY | -95.61% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 113.09% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Syros Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-776.96%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-25340.67%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-95.61%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "6.81%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-42.49%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-130.64%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.39%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-95.61%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "113.09%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | Abbvie (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 0.00 | 68/605 | - | - | - |
| PB | 0.00 | 455/605 | - | - | - |
| PS (TTM) | 0.03 | 8/605 | 2.09 | 0.17 | 0.03 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/SYRS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SYRS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SYRS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.